Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Gastroenterology

This article is part of the Research TopicInnovations in targeting intestinal immunity for chronic inflammatory disordersView all 23 articles

Leveraging Patient-Reported Outcomes and Serum Markers to Predict Active Ulcerative Colitis: A Multicenter Cohort

Provisionally accepted
Wenqian  LiWenqian Li1,2Xin  HaoXin Hao3,4Yunyun  SunYunyun Sun2Caimin  LiCaimin Li2Mei  WangMei Wang2Sicong  HouSicong Hou1,2*
  • 1Yangzhou University, Yangzhou, China
  • 2Affiliated Hospital of Yangzhou University, Yangzhou, China
  • 3Baoying People's Hospital, Yangzhou, China
  • 4Kangda College of Nanjing Medical University, Lianyungang, China

The final, formatted version of the article will be published soon.

Background and aim: This study aims to develop a score system via noninvasive and reliable clinical tools for individuals to distinguish remission and active Ulcerative Colitis (UC). Methods: We performed a retrospective multicenter study collecting 173 patients in the training cohort and 124 patients in the validation cohort with UC. Then we assessed the relationship between patient-reported outcomes (PROs) and serum indicators with endoscopic disease activity (defined as UCEIS ≥1). Univariate and multivariate logistic regression analyses were performed, with a stepwise backward selection approach used to select significant variables. Two predictive models were ultimately developed based on PROs and serum biomarkers. Results: A total of 173 and 124 patients were enrolled in the training and validation groups, respectively. Univariate and multivariate analyses revealed that stool frequency (SF), rectal bleeding (RB), CRP/TB, and PDW were significantly associated with endoscopic active UC. Two predictive models were developed, with SF (model A) and RB (model B) combined with CRP/TB and PDW, respectively. Both models demonstrated excellent discriminative ability for endoscopic activity, with area under the ROC curve (AUC) values of 0.906 (95% CI 0.863-0.949) and 0.899 (95% CI 0.855-0.943) in the training cohort. External validation cohort showS similar strong discriminative ability. In MES system, model A and model B exhibited AUC values of 0.894 and 0.884 in the training cohort, and 0.864 and 0.905 in the validation cohort. Subgroup analysis based on Montreal classification further validated the models' stability and reliability, with consistent performance across different disease locations. This is a provisional file, not the final typeset article Conclusion: The predictive models based on SF and RB developed in this study demonstrated good discriminative ability in predicting endoscopic activity in patients with UC. Both models performed well in the internal and external validation. Additional validation utilizing the MES and Montreal classification system provided further evidence supporting the reliability and effectiveness of these models. These findings underscored the potential clinical utility of the SF-and RB-based models as valuable tools for predicting endoscopic disease activity in UC patients, which could facilitate more informed clinical decision-making and improve patient outcomes in the management of UC.

Keywords: endoscopic activities, Patient-reportedoutcomes, predictive model, Serological indicators, ulcerative colitis

Received: 26 Nov 2025; Accepted: 16 Feb 2026.

Copyright: © 2026 Li, Hao, Sun, Li, Wang and Hou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sicong Hou

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.